Talking about bioavailability.

[GaumarolBostich]

As I wondered through the valleys of different drugs and researched on my way to be on the safer side as well to perfectionate my usage I would have loved an overview which ROA would provide which bioavailability. This doesn't exist, you have to collect the crumbs of knowledge from various sites with more or less accurateness and completeness. So I thought a compendium would be nice.

i will edit this post with your contributions. Pattern is like this:
"Substance" "ROA: Insufflated / Oral / Boofed" "% bioavailability" (Fill free to contribute which data is available at all. I think IV could be skipped, it should be nearly 100% with any substance) Please add the source of the data, best with a link.
Suggestions for improvements are welcome. Thank you!

 

[placebonaut]

just use chatGPT, you can ask it to add in references if you don't trust the data or go and search specifics. I eyeballed a few of the things that I know and this list below looks right for those things

1st prompt - create a harm reduction table for the 20 most commonly used drug classes include details of the drug class e.g. benzo, the different ROAs with the bioavailability of each, the dangers of taking via each ROA.

2nd prompt - update to create separate entries for drugs that have different bioavailabilites to other drugs in their class.

Drug class​	Specific drug​	Route of administration (ROA)​	Approx. bioavailability​	Onset​	Main route-specific dangers / harm reduction​
Opioid​	Heroin (diacetylmorphine)​	IV​	~100%​	Very rapid​	Highest overdose risk from rapid CNS delivery; vein damage, abscesses, endocarditis and blood-borne infections.​
Opioid​	Heroin​	Intranasal​	Variable / poorly established​	Rapid​	Nasal irritation and bleeding; variable absorption and unpredictable illicit-drug potency.​
Opioid​	Heroin​	Smoked/inhaled​	Highly variable​	Very rapid​	Rapid systemic delivery; respiratory irritation and burns; overdose remains possible.​
Opioid​	Fentanyl​	IV​	~100%​	Very rapid​	Extremely potent; small variations in exposure can cause respiratory depression. Injection adds infection and vascular risks.​
Opioid​	Fentanyl​	Intranasal​	~89% for some pharmaceutical formulations​	Rapid​	High systemic availability; nasal irritation/ulceration; illicit formulations are unpredictable.​
Opioid​	Fentanyl​	Buccal/transmucosal​	Formulation-dependent​	Rapid–moderate​	Substantial mucosal absorption; accidental exposure and formulation manipulation can produce uncontrolled dosing.​
Opioid​	Fentanyl​	Transdermal​	Formulation-dependent​	Slow​	Prolonged exposure; heating or manipulating patches can cause potentially dangerous uncontrolled drug release.​
Opioid​	Morphine​	Oral​	~20–30%​	Slow​	First-pass metabolism and delayed effects can encourage premature redosing; respiratory depression.​
Opioid​	Morphine​	IV​	~100%​	Very rapid​	Abrupt respiratory depression; vein damage, infection and endocarditis risk.​
Opioid​	Morphine​	Intranasal​	~10–30%​	Moderate–rapid​	Nasal injury and variable absorption; substantially lower bioavailability than IV.​
Opioid​	Oxycodone​	Oral​	~60–90%​	Moderate​	Delayed respiratory depression and accumulation; modified-release products are particularly dangerous if manipulated.​
Opioid​	Oxycodone​	Intranasal​	Formulation-dependent​	Rapid​	Nasal injury and faster systemic delivery; altered-release formulations may produce unpredictable exposure.​
Opioid​	Buprenorphine​	Sublingual​	~28–51%​	Moderate​	Prolonged opioid effect; dangerous sedation when combined with other CNS depressants.​
Opioid​	Buprenorphine​	Buccal​	~46–65%​	Moderate​	High transmucosal absorption; formulation-specific pharmacokinetics.​
Opioid​	Buprenorphine​	IV​	~100%​	Very rapid​	Injection-related infection and vascular injury; formulations containing naloxone may behave differently when injected.​
Opioid​	Buprenorphine​	Intranasal​	~38–44% in some studies​	Rapid​	Nasal injury and faster absorption; not equivalent to approved formulations.​
Benzodiazepine​	Diazepam​	Oral​	~90–100%​	Moderate​	Sedation, impaired coordination and respiratory depression, particularly with opioids or alcohol.​
Benzodiazepine​	Diazepam​	IV​	~100%​	Very rapid​	Abrupt profound sedation and respiratory depression, particularly with opioids.​
Benzodiazepine​	Alprazolam​	Oral​	~80–90%​	Moderate​	Amnesia, impaired judgement, dependence and dangerous CNS depression with other depressants.​
Benzodiazepine​	Alprazolam​	Sublingual​	High / formulation-dependent​	Faster​	Potentially faster CNS exposure; mucosal irritation; increased impairment.​
Benzodiazepine​	Lorazepam​	Oral​	~85–95%​	Moderate​	Sedation, amnesia and falls; respiratory depression with other CNS depressants.​
Benzodiazepine​	Lorazepam​	IM​	~90%​	Moderate​	Pain and tissue injury; absorption can be less predictable than oral administration.​
Benzodiazepine​	Midazolam​	Oral​	~30–50%​	Moderate​	Extensive first-pass metabolism; sedation and respiratory depression.​
Benzodiazepine​	Midazolam​	Intranasal​	Formulation-dependent; substantial​	Rapid​	Nasal irritation; rapid CNS effects and respiratory depression.​
Benzodiazepine​	Midazolam​	IV​	~100%​	Very rapid​	Significant respiratory depression; medical monitoring is normally required.​
Stimulant​	Cocaine​	Oral​	~30–60%​	Slow​	Delayed peak can encourage redosing; cardiovascular toxicity remains possible.​
Stimulant​	Cocaine​	Intranasal​	~60–80%​	Rapid–moderate​	Nasal vasoconstriction, bleeding, mucosal damage and possible septal injury.​
Stimulant​	Cocaine​	Smoked/freebase​	>90% in some studies​	Very rapid​	Rapid peak, strong reinforcement, pulmonary irritation and cardiovascular toxicity.​
Stimulant​	Cocaine​	IV​	~100%​	Very rapid​	Rapid cardiovascular/CNS toxicity; vein damage, abscesses, endocarditis and blood-borne infections.​
Stimulant​	Amphetamine​	Oral​	~70–90%​	Moderate​	Long duration; repeated dosing can cause insomnia, cardiovascular strain, hyperthermia and psychosis.​
Stimulant​	Amphetamine​	Intranasal​	High / variable​	Rapid​	Nasal injury and faster concentration rise.​
Stimulant​	Amphetamine​	IV​	~100%​	Very rapid​	Abrupt cardiovascular/CNS effects plus injection-related infections and vascular injury.​
Stimulant​	Methamphetamine​	Oral​	High​	Moderate​	Long duration; insomnia, agitation, hyperthermia, cardiovascular strain and psychosis.​
Stimulant​	Methamphetamine​	Intranasal​	High / variable​	Rapid​	Nasal injury and faster CNS exposure.​
Stimulant​	Methamphetamine​	Smoked​	High / variable​	Very rapid​	Rapid reinforcement, compulsive redosing, pulmonary irritation and cardiovascular toxicity.​
Stimulant​	Methamphetamine​	IV​	~100%​	Very rapid​	High acute-toxicity and injection-related risks.​
Entactogen​	MDMA​	Oral​	~65–80%​	Moderate​	Delayed peak can encourage redosing; hyperthermia, hyponatraemia and serotonin toxicity.​
Entactogen​	MDMA​	Intranasal​	Not well established​	Rapid​	Nasal injury and potentially sharper concentration peak.​
Dissociative​	Ketamine​	IV​	~100%​	Very rapid​	Abrupt dissociation; respiratory/CNS complications; injection-related infection and vascular damage.​
Dissociative​	Ketamine​	IM​	~90–95%​	Rapid​	Tissue injury and prolonged dissociation.​
Dissociative​	Ketamine​	Intranasal​	~8–45%​	Rapid​	Nasal injury and highly variable absorption.​
Dissociative​	Ketamine​	Oral​	~17–29%​	Slow​	Delayed and variable effects can encourage premature redosing.​
Dissociative​	DXM​	Oral​	~10–20% parent drug​	Slow–moderate​	Extensive first-pass metabolism; large person-to-person variation; high exposures can cause dissociation, seizures and serotonin toxicity.​
Cannabinoid​	Δ9-THC​	Smoked​	~10–35%​	Very rapid​	Lung exposure to combustion products; rapid intoxication and impaired coordination.​
Cannabinoid​	Δ9-THC​	Vaporized​	~10–35%, highly variable​	Very rapid​	Rapid systemic exposure; device and product variability.​
Cannabinoid​	Δ9-THC​	Oral​	~4–12%​	Slow​	Delayed and variable onset; prolonged intoxication makes premature redosing a major risk.​
Cannabinoid​	CBD​	Inhaled​	~11–45%​	Rapid​	Respiratory exposure; rapid systemic delivery.​
Cannabinoid​	CBD​	Oral​	~6%​	Slow​	Variable absorption and extensive first-pass metabolism; drug interactions are important.​
Psychedelic​	LSD​	Oral/buccal​	High; exact absolute F poorly established​	Slow–moderate​	Long duration; panic, impaired judgement and dangerous behaviour are the principal acute concerns.​
Psychedelic​	Psilocybin​	Oral​	Not usefully expressed as a simple absolute F​	Moderate​	Nausea, panic/anxiety and impaired judgement; converted to active psilocin after absorption.​
Psychedelic​	DMT​	Inhaled/vaporized​	Rapid absorption; absolute F not established​	Extremely rapid​	Abrupt onset can produce severe panic/dissociation and loss of coordination; burns possible with improvised equipment.​
Psychedelic​	DMT​	Oral + MAOI​	Highly formulation-dependent​	Slow​	MAO inhibition dramatically changes DMT pharmacology; potentially dangerous drug interactions.​
Depressant​	GHB​	Oral​	High; universal F not established​	Rapid​	Very narrow margin between intoxication and unconsciousness; respiratory depression, aspiration and coma.​
Depressant​	GBL​	Oral​	Rapidly converted to GHB​	Very rapid​	Particularly easy to overdose because onset and potency differ from GHB; profound CNS depression.​
Barbiturate​	Phenobarbital​	Oral​	~90–100%​	Slow​	Long half-life and accumulation; respiratory depression and dangerous withdrawal.​
Barbiturate​	Phenobarbital​	IV​	~100%​	Very rapid​	Severe CNS/respiratory depression; normally requires medical monitoring.​
Z-drug​	Zolpidem​	Oral​	~70%​	Moderate​	Amnesia, falls and complex sleep behaviours; greatly increased danger with alcohol/opioids.​
Z-drug​	Zolpidem​	Sublingual​	Formulation-dependent​	Faster​	Faster absorption can increase impairment; use only as formulated.​
Gabapentinoid​	Gabapentin​	Oral​	~60% at lower doses; decreases at higher doses​	Slow–moderate​	Saturable absorption; sedation and respiratory depression, particularly with opioids.​
Gabapentinoid​	Pregabalin​	Oral​	>90%​	Moderate​	Dizziness, sedation and impaired coordination; respiratory depression with opioids/CNS depressants.​
Nicotine​	Nicotine​	Smoked tobacco​	Variable; rapid systemic delivery​	Very rapid​	Combustion produces major pulmonary/toxicant exposure; rapid delivery reinforces dependence.​
Nicotine​	Nicotine​	Vaped​	Highly device/product-dependent​	Rapid​	Variable nicotine concentration; respiratory exposure and dependence.​
Nicotine​	Nicotine​	Oral/transmucosal​	Variable​	Moderate​	Nausea, vomiting and nicotine poisoning at excessive exposure.​
Nicotine​	Nicotine​	Transdermal​	Slow/sustained​	Slow​	Prolonged exposure; skin irritation; considerably slower CNS delivery.​
Alcohol​	Ethanol​	Oral​	~80–100% absorbed​	Moderate​	Acute poisoning, aspiration, accidents and respiratory depression; especially dangerous with opioids/benzodiazepines.​
Inhalant​	Nitrous oxide​	Inhaled​	Rapid pulmonary uptake; absolute F not normally reported​	Very rapid​	Hypoxia, unconsciousness and falls; chronic heavy exposure can cause functional B12 deficiency and neurological injury.​
Inhalant​	Butane/propane​	Inhaled​	Rapid pulmonary absorption​	Very rapid​	Potential fatal arrhythmias, hypoxia and CNS depression; fire/explosion and cold-injury risks.​
Synthetic cannabinoid​	Synthetic cannabinoid agonists​	Smoked/vaporized​	Compound-specific / not established​	Very rapid​	Highly variable potency; severe agitation, psychosis, seizures, hyperthermia and cardiovascular toxicity.​
Synthetic cathinone​	Mephedrone​	Oral​	Limited human data​	Moderate​	Repeated dosing can lead to cardiovascular strain, agitation and hyperthermia.​
Synthetic cathinone​	Mephedrone​	Intranasal​	Limited human data​	Rapid​	Nasal injury and faster concentration rise; cardiovascular toxicity.​
Synthetic cathinone​	3-MMC​	Oral​	Not established​	Moderate​	Variable illicit composition; cardiovascular and hyperthermic toxicity.​
Synthetic cathinone​	3-MMC​	Intranasal​	Not established​	Rapid​	Nasal damage and potentially sharper concentration peaks.​
Anticholinergic​	Diphenhydramine​	Oral​	~40–70%​	Moderate​	High exposures can cause delirium, seizures, hyperthermia, arrhythmias and coma.​
Anticholinergic​	Atropine/scopolamine-type drugs​	Oral / medical parenteral​	Drug/formulation-specific​	Variable​	Anticholinergic delirium, tachycardia, hyperthermia, urinary retention and seizures at toxic exposure.​

 

[GaumarolBostich]

Thank you. But ... you trust ChatGPT?

It tends to be satisfied with the most popular sources and often mixes facts with rumours.
For example:
"Mephedrone, Oral, Limited human data". I remember that I discovered an exact number in a study. (And naturally forgot where).
"Cocaine, Oral, 30 - 60%" This would double the dose if you are assuming the lowest bioavailability.
Boofing is not mentioned at all. Should be the hardest to fill due to the exotism of it.

I discover in that generated table a lot of at least questionable writings. Where was this data gathered? psychonautwiki or Reddit?

I am convinced that a bunch of human experts can do better.

 

[placebonaut]

Thank you. But ... you trust ChatGPT?

trust is a strong word.

for the more basic and general info it tends to be ok, lots of the things on this list are pretty well researched and that's where chatGPT tends to be more solid in it's answers. The more exotic stuff I'd have less confidence in, but the easy way to check is ask it to include papers that reference the numbers, then it's pretty easy to click through if you have any doubts.

worth considering what you're trying to do with this info though, generally most rec drugs you want to take will have pretty well established ROAs e.g. smoking is best, don't bother eating it. Most people have no clue what the bioavilability of things are via different ROAs, you see it on BL all the time. Scanning down the list I'm looking for relative differences between ROAs for certain drugs, and I'm looking for the ball park numbers I would expect, these are all within the sorts of ranges I'd expect for the drugs I take but my knowledge is limited for some areas e.g. psychedelics/Opiates.

You shouldn't be using any info like this to help you decide doses or ROAs though, yes it's useful info to help inform, but better HR practice is to start small whatever your ROA. That way you don't trust your life on accuracy of bioavailability numbers, just knowing that that X ROA is better/stronger than Y so take less of it, or A is more dangerous than B so half your amount.

if nothing else this is a good starting point for your project, a lot less effort to just verify what it says via a click and quick search

think there's some bioavailability info on https://erowid.org/ but you might need to dig for it.

few things on here too.

Recreational dosages of common illicit drugs — Grokipedia

Recreational dosages of common illicit drugs refer to approximate amounts of substances such as morphine, heroin, fentanyl, cocaine, MDMA, LSD, and ketamine that individuals report using for non-medic

grokipedia.com

I am convinced that a bunch of human experts can do better.

The human experts publish papers on it, that's where people on here and chatGPT get the info, it's just about the leg work of pulling it together in the 1st place, and then the effort and labor to verify it

 

[placebonaut]

oh 1 after thought, another approach is to just ask people to throw bricks at the chatGPT data (it's not mine so I don't give a shit, I just know it was a very easy thing to do so thought worth giving an example is all), point out what is wrong and/or where there's better data.

references/links to back up the info would be good too!

afraid I think you'll struggle to get much input, those who already know know, and lots of the info is most likely already here on the forum if you just search for it, which is what most people likely will just do drug by drug anyway.

oh and I included onset as this and bioavailability are factors that drive peak plasma levels

 

[GaumarolBostich]

I agree on what say. Thank you for the effort, taking this "project" for real and sharing your thoughts.

I am on vacation atm, so I have some time to spend on things that are not effective but can be interesting.

Excellent idea to let falsecheck Chat GTP! This wakes the sportsmanship in nerds. Wit experts I meant the people here, so much knowledge gathered here.

Yes, there is so much knowledge hidden in papers where the termination of the bioavailability is a sideproduct.

 

[placebonaut]

I'll follow the thread with interest and might even chip in from time to time.

forgot to mention, you'd not getting any data on boofing....so it's just gonna be anecdotal...and a right pain in the arse to find